Sign in
CompletedNo phase

SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis

Key facts

Who runs it
Nantes University Hospital
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
9 people enrolled
Started
9 Jun 2024
Ended
30 Sept 2024
Type of study
Observational
Record updated
19 November 2026

Who can take part

Age
12 years to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (4)Hide the full registry criteria

Who can take part

  • Patients from 12 to 18 years old, on January the 1st 2022
  • Patients followed up from juvenile arthritis
  • Patients followed up in 2021 and 2022

Who cannot take part

  • Patients under 12 years old

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Since june 2021, vaccination against the SARS-Cov2 virus is recommanded in France to all children from 12 to 18 years old. In the specific population of teenagers living with juvenile arthritis, the vaccine seems to be safe and well tolerated. It has been shown previously that this population has a vaccine coverage lower than the global population even though few datas are available on this topic The aim of this resarch is to study the vaccination coverage against the SARS-Cov2 virus and more specifically the reasons why adolescents were or were not vaccinated in the population of adolescents with juvenile arthitis followed up in Angers, Nantes and Rennes. For this purpose, a review of the medical record will be done and a questionnaire will be adressed to the family of patients in order to collect informations about the disease, the treatments, the motives or obstacles to vaccination. Secondaries end points are safety of the vaccination, consequences on the juvenile arthritis (such as changes in the medication, flare-up of the illness) and the occurence of covid infection after vaccination.

The group in the trial

  • Trial population

    Children from 12 to 18 years old followed up for juvenile arthritis in Angers, Nantes and Rennes.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
SARS Cov2 Vaccination in Adolescents From 12 to 18 With Juvenile Idiopathic Arthritis in Angers, Nantes and Rennes : Acceptance and Safety.
Record updated
19 November 2026